Clinical Lung Cancer

Papers
(The H4-Index of Clinical Lung Cancer is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Transarterial Embolization for the Management of Emergent Hemoptysis in Patients With Primary and Metastatic Lung Tumors88
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibito82
Correlation of PET-CT, Endobronchial Ultrasound Cytology and Surgical Biopsy in Patients with Non-Small Cell Lung Cancer Undergoing Curative Surgery68
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics54
Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.53
Comments on “Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma”50
Untapping the Prognostic Value of Patient-Generated Health Data in Locally Advanced Non-small Cell Lung Cancer49
Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report49
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations45
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer40
Adequate Number of Lymph Nodes Sampled May Determine Appropriate Surgical Modality for Early-Stage NSCLC: A Population-Based Real-World Study40
Correspondence on SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies39
Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy35
Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients35
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer34
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status34
Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations33
Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy33
Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma32
Coexistence of a Novel BABAM2-ALK and EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Alectinib: The First Case Report29
Table of Contents29
Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator28
A National Survey of Surgeons Evaluating the Accuracy of Mediastinal Lymph Node Identification27
Editorial Board25
Intraoperative Versus Preoperative Diagnosis of Lung Cancer: Differences in Treatments and Patient Outcomes25
Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting25
DUPLICATE: Cancers of the Pancreas Update 202325
0.27944397926331